Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mononuclear cells (CellPraxis)
- Development stage
- Unknown
- Lead developer
- CellPraxis
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
Autologous bone marrow mononuclear cells (BMMCs) is a cell-based biologic therapy developed by CellPraxis Bioengenharia Ltda. for the treatment of refractory angina. The therapy involves harvesting mononuclear cells from the patient's own bone marrow and delivering them via direct intramyocardial injection into ischemic regions of the heart. The primary mechanism of action is therapeutic neovascularization, where the transplanted cells are hypothesized to induce neoangiogenesis (the formation of new blood vessels) in chronically ischemic cardiac tissue. This process aims to improve myocardial perfusion and reduce anginal symptoms in patients with advanced coronary artery disease who are not candidates for conventional revascularization procedures. The therapy was evaluated in the Phase II ReACT (Refractory Angina Cell Therapy) study.
- Other names
- autologous bone marrow stem cellsBMMCsautologous bone marrow mononuclear cells
Beyond the preview
Go deeper on autologous bone marrow mononuclear cells (CellPraxis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mononuclear cells (CellPraxis).